Extemporaneous drug preparations, which are compounded by a pharmacist at a clinical site, are commonly used in early clinical studies to evaluate the performance of drug candidates. However, the types of formulations compounded have been limited to relatively simple preparations such as solutions, suspensions and active ingredients filled into capsules. This article describes the preparation of advanced formulations, specifically extemporaneously prepared matrix tablets and osmotic capsules, which can be used to evaluate the feasibility of controlled release for exploratory new drug candidates or new formulations of existing drugs with a differentiated medical advantage. Extemporaneously prepared dosage forms enable the rapid assessment (i.e. reduced cycle time) of new formulation ideas with minimal quantity of the active pharmaceutical ingredient needed to demonstrate proof-of-concept.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2014.02.001DOI Listing

Publication Analysis

Top Keywords

extemporaneously prepared
12
drug candidates
12
controlled release
8
prepared controlled
4
formulations
4
release formulations
4
formulations accelerating
4
accelerating early
4
early phase
4
phase development
4

Similar Publications

Background: Extemporaneous compounding for dermatological use is an important therapeutic alternative for patients whose clinical needs are not met by approved drug products circulated in the market. Evaluating patients' perceptions and levels of satisfaction towards such services is an important factor for the adherence of patients and maintaining the quality of healthcare services. The current study aimed to assess patients' perception and level of satisfaction with the compounding service and extemporaneous preparations rendered at ALERT hospital.

View Article and Find Full Text PDF

Objective: In the United States, ursodiol is commercially available as solid dosage forms, which represents a problem for children who cannot swallow capsules or tablets. There is a lack of an age-appropriate formulation for ursodiol, and the extemporaneous preparation of an oral suspension with an extended beyond-use-date (BUD) may represent a good therapeutic alternative for the pediatric population. However, all pharmacists need validated stability studies to prepare oral liquids with high quality and safety.

View Article and Find Full Text PDF
Article Synopsis
  • Topical preparations, especially in dermatology, account for a significant portion of compounded prescriptions and involve varied ointment bases with active ingredients often added in liquid forms.
  • There are currently no established quantitative guidelines on how different ointment bases absorb water and alcohol, prompting a short experiment to measure their capacity for these solvents.
  • The findings aim to help compounding pharmacists choose the most appropriate base based on the solvent requirements for effective topical medications, while also offering insights into compounding challenges related to these preparations.
View Article and Find Full Text PDF
Article Synopsis
  • Chloral hydrate is a sedative used mainly in children for procedures like dental sedation and can be adapted for different patient needs due to a lack of commercially available age-appropriate forms.
  • Researchers created a customizable oral liquid formulation of chloral hydrate using a suspending vehicle called PCCA SuspendIt, which is free from sugar, dyes, and gluten, to improve dosing accuracy for both pediatric and adult patients.
  • The study aimed to develop and validate a stability-indicating assay using ultra-high-performance liquid chromatography (UPLC) to ensure the chemical stability of chloral hydrate at varying concentrations.
View Article and Find Full Text PDF

Background: Propranolol, largely prescribed as an antihypertensive and antiarrhythmic drug in pediatrics, is characterized by a bitter taste and an astringent aftertaste. Currently, the therapy requires crushing of tablets for adults and their dispersion in water many times a day, leading to loss of dosing accuracy, low palatability, and poor compliance for both patients and caregivers.

Objectives: This work aimed to exploit cyclodextrin complexation by cogrinding to develop orally disintegrating tablets (ODTs) endowed with reliable dosing accuracy, good palatability and safety, ease of swallowability, and ultimately better compliance for both pediatric patients and caregivers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!